GLP1R and type 2 diabetes mellitus: Exenatide infusion increases UEUA in males who are overweight and in T2DM patients; however, long-term GLP-1 receptor antagonist use has no effect on UA or UEUA in T2DM patients who have normal UA levels and low cardiovascular risk. This implies that the cardio-renal benefits of GLP-1 receptor antagonists are not mediated by UA changes.